checkAd
    Startseite > Aktien > Molecular Partners > Nachrichten
    Molecular Partners Aktie
    3,3550
     
    EUR
    0,00 %
    0,0000 EUR
    Letzter Kurs 18.05.24 Lang & Schwarz
    3,3050
     
    EUR
    2.770 STK
    Geldkurs 18.05.24
    3,4050
     
    EUR
    2.770 STK
    Briefkurs 18.05.24
    ISIN: CH0256379097 · WKN: A12DEH · Schweiz

    Neueste Nachrichten

    Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program
    16.05.24 · globenewswire · Molecular Partners
    Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action 
    29.04.24 · globenewswire · Molecular Partners
    Life Science Cares Launches in Switzerland
    19.04.24 · globenewswire · Molecular Partners
    Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
    17.04.24 · globenewswire · Molecular Partners
    Molecular Partners Publishes Invitation to Annual General Meeting 2024
    26.03.24 · globenewswire · Molecular Partners
    Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
    14.03.24 · globenewswire · Molecular Partners
    Molecular Partners Announces Dismissal of Class Action Lawsuit
    01.03.24 · globenewswire · Molecular Partners
    Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
    01.03.24 · globenewswire · Molecular Partners
    Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
    07.01.24 · globenewswire · Molecular Partners
    Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
    05.01.24 · globenewswire · Molecular Partners
    Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)
    14.11.23 · globenewswire · Molecular Partners
    Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting
    03.11.23 · globenewswire · Molecular Partners